ConcertAI’s TeraRecon Offers New Suite to Eureka Clinical AI Platform
Cardio Suite to reportedly provide clinicians with artificial intelligence technology to help fight cardiovascular disease.
ConcertAI’s TeraRecon, a clinical AI SaaS company, broke the news that its Eureka Clinical AI platform's Cardio Suite now provides clinicians with the artificial intelligence and deep learning technology necessary to help identify, treat, and manage cardiovascular disease.
"The Cardio Suite represents our second installment of dedicated care area suites following the launch of the Neuro Suite earlier this year," said Dan McSweeney, President, TeraRecon. "We are committed to supporting cardiologists and clinicians by bringing novel AI powered solutions, such as our Cardio Suite, forward to more efficiently help physicians screen and diagnose cardiac disease patients so that appropriate treatments can be delivered."
Reference: ConcertAI's TeraRecon Adds Cardio Suite to its Eureka Clinical AI Platform. PR Newswire. August 30, 2023. Accessed September 5, 2023. https://www.prnewswire.com/news-releases/concertais-terarecon-adds-cardio-suite-to-its-eureka-clinical-ai-platform-301912876.html
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025